Pharmaceuticals
Alternative labels
Medication
Pharmaceutical industry
Briefing paper
Assessing the utility of Project STOP in reducing pseudoephedrine diversion to clandestine laboratories
Evaluates the utility of Project STOP in reducing the diversion of PSE-based products to clan labs. Foreword Project STOP, an online database in which pharmacists record sales of pseudoephedrine (PSE)-based medication, was implemented in 2005 to aid in reducing the diversion of PSE-based products for use as precursors in the domestic manufacture of methamphetamine. Australian...
Article
The TPP’s one-way ratchet
Australia gained some concessions in the Trans-Pacific Partnership negotiations. But this is still the wrong way to manage our international trade and investment, writes John Quiggin.
Article
Too much medicine: fear exploited for profit
While people in the affluent world are living longer and healthier lives than ever before, they have become more and more fearful and worried about their health. Iona Heath untangles the distinct yet overlapping fears of patients, doctors, bureaucrats, politicians and society at large. In about 1848, while writing his famous poem The Bells, Edgar...
Report
Implementing medicines New Zealand 2015 to 2020
Summary Medicines play a significant role in helping New Zealanders get well, stay well and live well. We have already made positive changes in this area, but there are substantial challenges ahead of us. We need to buy, use and manage medicines wisely. We need to meet the needs of our ageing population and meet...
Report
Premium policy? Getting better value from the PBS
Overview: Poor implementation of a policy to get better value for PBS spending is costing government $320 million a year and raising questions about pharmaceutical industry involvement in drug pricing. The therapeutic group premium policy, introduced in 1998 to stop the government wasting money on over-priced drugs, has been so watered down that it is...